

# Philipp Harter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7019575/publications.pdf>

Version: 2024-02-01

50  
papers

7,969  
citations

236612

25  
h-index

223531

46  
g-index

51  
all docs

51  
docs citations

51  
times ranked

7143  
citing authors

#	ARTICLE	IF	CITATIONS
1	Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 468-473.	1.2	0
2	Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring. <i>Cancers</i> , 2022, 14, 168.	1.7	5
3	Clonal Hematopoiesis—Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 565-570.	3.0	17
4	Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e82.	1.0	6
5	A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer. <i>Cancers</i> , 2021, 13, 1764.	1.7	7
6	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 620-631.	5.1	215
7	Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation — real life data. <i>Gynecologic Oncology</i> , 2021, 163, 569-577.	0.6	7
8	Ovarian Cancer—Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6559-6569.	3.2	9
9	PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations. <i>Cancer Treatment Reviews</i> , 2021, 99, 102255.	3.4	25
10	Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. <i>European Journal of Cancer</i> , 2021, 154, 190-200.	1.3	9
11	Early-stage epithelial ovarian cancer: is systematic lymph node staging mandatory?. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e61.	1.0	5
12	The role of factor XIII in surgery for advanced stage of epithelial ovarian cancer. <i>Archives of Gynecology and Obstetrics</i> , 2021, , 1.	0.8	0
13	Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?. <i>Cancers</i> , 2021, 13, 5756.	1.7	11
14	Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2123-2131.	13.9	144
15	Prevalence of BRCA1 and BRCA2 Mutations in Patients with Primary Ovarian Cancer — Does the German Checklist for Detecting the Risk of Hereditary Breast and Ovarian Cancer Adequately Depict the Need for Consultation?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 932-940.	0.8	7
16	Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer — a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34). <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1997-2001.	1.2	11
17	TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR) Tj ETQq1 1 0.784314 rgBT /Ov	1.2	108
18	Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). <i>Journal of Medical Genetics</i> , 2019, 56, 574-580.	1.5	34

#	ARTICLE	IF	CITATIONS
19	A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. <i>New England Journal of Medicine</i> , 2019, 380, 822-832.	13.9	373
20	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	13.9	1,176
21	Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2018, 25, 2053-2059.	0.7	36
22	Is there a role for HIPEC in ovarian cancer?. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 859-860.	0.8	6
23	Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis. <i>Human Mutation</i> , 2018, 39, 2040-2046.	1.1	20
24	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	1.8	3
25	A new standard of care or just another option for patients with relapsed ovarian cancer?. <i>Lancet Oncology</i> , 2017, 18, 701-702.	5.1	0
26	Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 444-451.	1.2	18
27	Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study. <i>Annals of Surgical Oncology</i> , 2017, 24, 2720-2726.	0.7	44
28	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1274-1284.	5.1	1,376
29	Brief Report About the Role of Hyperthermic Intraperitoneal Chemotherapy in a Prospective Randomized Phase 3 Study in Recurrent Ovarian Cancer From Spiliotis et al. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 246-247.	1.2	44
30	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). <i>PLoS ONE</i> , 2017, 12, e0186043.	1.1	105
31	LION: Lymphadenectomy in ovarian neoplasms—A prospective randomized AGO study group led gynecologic cancer intergroup trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5500-5500.	0.8	81
32	Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Oncology</i> , 2016, 17, 1579-1589.	5.1	380
33	Impact of Abdominal Wall Metastases on Prognosis in Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1594-1600.	1.2	23
34	BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. <i>Gynecologic Oncology</i> , 2016, 140, 443-449.	0.6	47
35	Prognostic value of lymph node ratio in patients with advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 135, 435-440.	0.6	57
36	Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5). <i>Gynecologic Oncology</i> , 2014, 133, 427-432.	0.6	40

#	ARTICLE	IF	CITATIONS
37	Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 537-541.	0.6	32
38	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 852-861.	5.1	1,237
39	In Reply: Response to Sammartino et al.. <i>Current Oncology Reports</i> , 2013, 15, 192-192.	1.8	0
40	Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). <i>Investigational New Drugs</i> , 2013, 31, 1499-1504.	1.2	19
41	Surgery for Relapsed Ovarian Cancer: When Should it Be Offered?. <i>Current Oncology Reports</i> , 2012, 14, 539-543.	1.8	20
42	Bevacizumab in the Treatment of Ovarian Cancer. <i>Advances in Therapy</i> , 2012, 29, 723-735.	1.3	33
43	Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 289-295.	1.2	239
44	Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2011, 121, 615-619.	0.6	166
45	Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 81-88.	1.1	46
46	Role of cytoreductive surgery in recurrent ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 917-922.	1.1	12
47	Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. <i>Cancer</i> , 2009, 115, 1234-1244.	2.0	1,270
48	Prognostic Factors for Complete Debulking in First- and Second-Line Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, S14-S17.	1.2	21
49	Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. <i>Annals of Surgical Oncology</i> , 2006, 13, 1702-1710.	0.7	367
50	The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence. <i>Current Opinion in Oncology</i> , 2005, 17, 505-514.	1.1	58